Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-22
DOI
10.1186/s12885-020-07167-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
- (2019) Yoshihiro Miyasaka et al. ANNALS OF SURGICAL ONCOLOGY
- Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
- (2018) Shuhei Shinoda et al. Oncotarget
- Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
- (2017) Theodoros Michelakos et al. ANNALS OF SURGERY
- Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
- (2016) Hirofumi Harima et al. BMC CANCER
- Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
- (2016) J S Ankeny et al. BRITISH JOURNAL OF CANCER
- Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer
- (2016) Seishi Nishitani et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- (2016) Naoki Yamamoto et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
- (2016) Issei Saeki et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation
- (2015) Ying Yan et al. Oncotarget
- Deferasirox (ICL670A) effectively inhibits oesophageal cancer growthin vitroandin vivo
- (2012) SJ Ford et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)
- (2012) Zhiqiang Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cdc42 in oncogenic transformation, invasion, and tumorigenesis
- (2011) Kristy Stengel et al. CELLULAR SIGNALLING
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Deferoxamine for Advanced Hepatocellular Carcinoma
- (2011) Takahiro Yamasaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
- (2009) Junko H. Ohyashiki et al. CANCER SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More